CL2024003460A1 - Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos. - Google Patents

Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos.

Info

Publication number
CL2024003460A1
CL2024003460A1 CL2024003460A CL2024003460A CL2024003460A1 CL 2024003460 A1 CL2024003460 A1 CL 2024003460A1 CL 2024003460 A CL2024003460 A CL 2024003460A CL 2024003460 A CL2024003460 A CL 2024003460A CL 2024003460 A1 CL2024003460 A1 CL 2024003460A1
Authority
CL
Chile
Prior art keywords
oxoindolinyl
amide derivatives
inhibiting nlrp3
treatment
methods
Prior art date
Application number
CL2024003460A
Other languages
English (en)
Spanish (es)
Inventor
Dorich Stéphane
Burch Jason
St-Onge Miguel
Côté Alexandre
Beveridge Ramsay
Ciblat Stéphane
CYR Patrick
Original Assignee
Ventus Therapeutics U S Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics U S Inc filed Critical Ventus Therapeutics U S Inc
Publication of CL2024003460A1 publication Critical patent/CL2024003460A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2024003460A 2022-05-13 2024-11-12 Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos. CL2024003460A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263341614P 2022-05-13 2022-05-13

Publications (1)

Publication Number Publication Date
CL2024003460A1 true CL2024003460A1 (es) 2025-04-11

Family

ID=86760226

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024003460A CL2024003460A1 (es) 2022-05-13 2024-11-12 Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos.

Country Status (15)

Country Link
US (1) US20240368131A1 (enExample)
EP (1) EP4522591A1 (enExample)
JP (1) JP2025516719A (enExample)
KR (1) KR20240172228A (enExample)
CN (1) CN119212978A (enExample)
AU (1) AU2023268557A1 (enExample)
CA (1) CA3251062A1 (enExample)
CL (1) CL2024003460A1 (enExample)
CO (1) CO2024015371A2 (enExample)
IL (1) IL316674A (enExample)
JO (2) JOP20240258A1 (enExample)
MX (1) MX2024013978A (enExample)
PE (1) PE20251252A1 (enExample)
TW (1) TW202409013A (enExample)
WO (1) WO2023220715A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20252770A1 (es) * 2023-03-17 2025-12-22 Ventus Therapeutics U S Inc Derivados de amida para inhibir nlrp3 y usos de estos
CN122206665A (zh) * 2023-11-15 2026-06-12 万特斯治疗美国公司 用于抑制nlrp3的内酰胺衍生物及其用途
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3

Also Published As

Publication number Publication date
WO2023220715A1 (en) 2023-11-16
US20240368131A1 (en) 2024-11-07
CO2024015371A2 (es) 2024-12-30
PE20251252A1 (es) 2025-05-06
EP4522591A1 (en) 2025-03-19
CA3251062A1 (en) 2023-11-16
KR20240172228A (ko) 2024-12-09
TW202409013A (zh) 2024-03-01
JOP20240257A1 (ar) 2024-11-12
JP2025516719A (ja) 2025-05-30
IL316674A (en) 2024-12-01
MX2024013978A (es) 2024-12-06
CN119212978A (zh) 2024-12-27
AU2023268557A1 (en) 2024-11-14
JOP20240258A1 (ar) 2024-11-12

Similar Documents

Publication Publication Date Title
CO2024015371A2 (es) Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
CO2023001407A2 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CR20230616A (es) Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn)
PE20240881A1 (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
AR070299A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas
UY39032A (es) Compuestos heterocíclicos como agentes antivirales
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
BR112023003832A2 (pt) Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
BR112022009209A2 (pt) Derivado de amida e método de preparação e uso do mesmo na medicina
MX2024011697A (es) Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de proteinas que contienen el dominio de pirina de la familia de los receptores similares al dominio de oligomerizacion de union a nucleotido 3 (nlrp3)
UY39799A (es) Compuestos de pirrolil–sulfonamida
UY39642A (es) Compuestos heterocíclicos antivirales
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
UY40282A (es) Compuestos amido-heteroaromáticos
AR133250A1 (es) Nuevos compuestos
CL2025001819A1 (es) Compuestos derivados de tiadiazol y uso como inhibidores de cgamp sintasa (cgas).
MX2026001703A (es) Preparacion farmaceutica de un derivado de piperazina, metodo de preparacion de la misma y uso de la misma
MX2021012392A (es) Compuestos, composiciones y metodos.